Prof. Li Cai 蔡莉
Chief Physician, Professor
Department of Medical Oncology (II), Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, endocrine therapy, and biological targeted therapy for early- and late-stage breast cancer.
Dr. Cai has worked in medical oncology for nearly 20 years at Harbin Medical University Cancer Hospital. Dr. Cai completed a one-year fellowship in internal medicine at Nippon Medical School in Japan in 2002. Research focuses on mechanisms of chemotherapy drug resistance to support individualized treatment plans. Dr. Cai holds a PhD in oncology and completed postdoctoral work at China Medical University.
Professional roles
- Executive Committee Member, Chinese Society of Clinical Oncology (CSCO)
- Committee Member, CSCO Vascular Targeted Therapy Expert Committee
- Youth Committee Member, Breast Cancer Professional Committee, China Anti-Cancer Association
- Editorial Board Member, Chinese Journal of Oncology
Name order: in Chinese the family name comes first (Cai Li). Papers usually list the name as Li Cai or Cai L.
Selected publications
84 papers on PubMed matched by name and affiliation; 24 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Commun (Lond), 2025 (senior author): m(6)A-modified EHD1 controls PD-L1 endosomal trafficking to modulate immune evasion and immunotherapy responses in lung adenocarcinoma. PubMed 40703029
- Mol Med Rep, 2025 (senior author): [Retracted] PADI4‑mediated epithelial‑mesenchymal transition in lung cancer cells. PubMed 40641113
- Cancer Cell Int, 2024 (senior author): DUSP5 regulated by YTHDF1-mediated m6A modification promotes epithelial-mesenchymal transition and EGFR-TKI resistance via the TGF-β/Smad signaling pathway in lung adenocarcinoma. PubMed 38872157
- BMC Cancer, 2023 (senior author): Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial. PubMed 37208633
- Front Genet, 2022 (senior author): Comprehensive analysis of karyopherin alpha family expression in lung adenocarcinoma: Association with prognostic value and immune homeostasis. PubMed 35991543
- J Oncol, 2021 (senior author): Identification of Differentially Expressed and Prognostic lncRNAs for the Construction of ceRNA Networks in Lung Adenocarcinoma. PubMed 34987577
- Front Oncol, 2020 (senior author): Targeting 14-3-3ζ Overcomes Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma via BMP2/Smad/ID1 Signaling. PubMed 33123465
- J Exp Clin Cancer Res, 2019 (senior author): Mammalian Eps15 homology domain 1 potentiates angiogenesis of non-small cell lung cancer by regulating β2AR signaling. PubMed 31023336
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion